URL path: Index page // Anti-Gliadin sIgA, Stool

Anti-Gliadin sIgA, Stool

Anti-gliadin secretory Immunoglobulin A (sIgA) in stool is an essential marker for gluten sensitivity and related gastrointestinal disorders, such as celiac disease and non-celiac gluten sensitivity (NCGS). Gliadin is a component of gluten, a protein found in wheat, barley, and rye. The immune response to gliadin involves the production of antibodies, including sIgA, which play a crucial role in mucosal immunity.

The measurement of anti-gliadin sIgA in stool is particularly valuable for diagnosing gluten-related disorders, monitoring adherence to a gluten-free diet, and assessing mucosal immune response. Its non-invasive nature makes it preferable, especially for pediatric patients and those reluctant to undergo blood tests or biopsies.

Celiac Disease

  • An autoimmune disorder triggered by the ingestion of gluten in genetically predisposed individuals.
  • Symptoms include chronic diarrhea, abdominal pain, bloating, and malabsorption, leading to nutritional deficiencies.
  • Diagnosis typically involves serological testing for tissue transglutaminase (tTG) and endomysial antibodies (EMA), followed by confirmatory duodenal biopsy.
  • Anti-gliadin sIgA in stool can support the diagnosis, particularly in cases where serological tests are inconclusive or in patients with IgA deficiency.

Non-Celiac Gluten Sensitivity (NCGS)

  • A condition where individuals experience symptoms related to gluten ingestion without the autoimmune damage seen in celiac disease.
  • Symptoms overlap with celiac disease and irritable bowel syndrome (IBS), including abdominal pain, bloating, diarrhea, and fatigue.
  • Diagnosis is primarily clinical, based on symptom relief after gluten withdrawal and the exclusion of celiac disease and wheat allergy.
  • Measurement of anti-gliadin sIgA in stool can help identify immune responses to gluten in these patients.

Monitoring Gluten-Free Diet (GFD) Compliance

  • For individuals diagnosed with celiac disease, strict adherence to a GFD is crucial to manage symptoms and prevent complications.
  • Anti-gliadin sIgA levels in stool can be monitored to assess dietary compliance. These levels typically decrease upon strict elimination of gluten from the diet.

No special preparation is usually required, although patients should avoid excessive gluten intake or elimination just before the test.

Interpretation of Results

  • Elevated levels of anti-gliadin sIgA in stool suggest an immune response to gluten.
  • In celiac disease, high levels may indicate ongoing gluten exposure or poor dietary compliance.
  • In NCGS, elevated sIgA supports the diagnosis, although further evaluation and clinical correlation are necessary.

The measurement of anti-gliadin sIgA in stool is valuable in diagnosing and managing gluten-related disorders. Its non-invasive nature and ability to reflect mucosal immune responses make it particularly useful in clinical practice.

Additional information
Share it